CENTOGENE Supports Tajikistan in Fight Against the COVID-19 Pandemic
August 04 2020 - 6:30AM
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on rare diseases that transforms real-world clinical and genetic
data into actionable information for patients, physicians, and
pharmaceutical companies, announced today that it has expanded its
ongoing development cooperation with the Ministry of Health and
Social Protection of the Population of Tajikistan to now include
SARS-CoV-2 testing.
The project will enable Tajikistan to increase
their testing capacities – helping the country to identify and
quarantine patients with a SARS-CoV-2 infection and hence, control
infection chains to minimize the outbreak of COVID-19. In the
framework of this not-for-profit project, the National Reference
Laboratory (NRL) in Dushanbe has received reagents, laboratory
devices, swabs, and transport systems for qPCR
testing.
CENTOGENE will train the Tajik experts to
conduct SARS-CoV-2 testing using Standard Operating Procedures
(SOPs) and training tools in development by CENTOGENE scientists,
with follow-up audiovisual consultations to address future
questions and quality management related challenges.
“Building on our valuable experiences within the
ongoing cooperation with CENTOGENE, we highly welcome this
initiative to enhance COVID-19 diagnosis for patients in
Tajikistan,” said Dr. Gafur Muhsinzoda, First Deputy Minister of
Health in Tajikistan.
Prior to this initiative, CENTOGENE signed a
memorandum of understanding with the Ministry of Health in July
2019 to cooperate in the field of rare diseases. The project
consists of three cornerstones: training of Tajik doctors, pro bono
diagnostic of patients and support to affected families with
information, and access to patient networks. It is jointly funded
by CENTOGENE and the develoPPP.de program of the German Federal
Ministry for Economic Cooperation and Development
(Bundesministerium für Wirtschaftliche Zusammenarbeit und
Entwicklung (BMZ)).
Prof. Arndt Rolfs, CEO of CENTOGENE, stated,
“This co-funding partnership represents an innovative way to work
in close cooperation with the public sector – supporting countries
with much needed help for pressing healthcare challenges. In the
midst of recent obstacles, it is important to continue working
together to increase testing efforts and diagnose patients at the
earliest possible point.”
About CENTOGENE
CENTOGENE engages in diagnosis and research
around rare diseases transforming real-world clinical and genetic
data into actionable information for patients, physicians, and
pharmaceutical companies. Our goal is to bring rationality to
treatment decisions and to accelerate the development of new orphan
drugs by using our extensive rare disease knowledge, including
epidemiological and clinical data, as well as innovative
biomarkers. CENTOGENE has developed a global proprietary rare
disease platform based on our real-world data repository with
approximately 3.0 billion weighted data points from over 530,000
patients representing over 120 different countries as of March 31,
2020.
The Company’s platform includes epidemiologic,
phenotypic, and genetic data that reflects a global population, and
also a biobank of these patients’ blood samples. CENTOGENE believes
this represents the only platform that comprehensively analyzes
multi-level data to improve the understanding of rare hereditary
diseases, which can aid in the identification of patients and
improve our pharmaceutical partners’ ability to bring orphan drugs
to the market. As of March 31, 2020, the Company collaborated with
39 pharmaceutical partners covering over 45 different rare
diseases.
Important Notice and
Disclaimer
This press release contains statements that
constitute “forward looking statements” as that term is defined in
the United States Private Securities Litigation Reform Act of 1995,
including statements that express the Company’s opinions,
expectations, beliefs, plans, objectives, assumptions or
projections regarding future events or future results, in contrast
with statements that reflect historical facts. Examples include
discussion of our strategies, financing plans, growth opportunities
and market growth. In some cases, you can identify such
forward-looking statements by terminology such as “anticipate,”
“intend,” “believe,” “estimate,” “plan,” “seek,” “project” or
“expect,” “may,” “will,” “would,” “could” or “should,” the negative
of these terms or similar expressions. Forward looking statements
are based on management’s current beliefs and assumptions and on
information currently available to the Company. However, these
forward-looking statements are not a guarantee of our performance,
and you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, such as negative worldwide
economic conditions and ongoing instability and volatility in the
worldwide financial markets, the effects of the COVID-19 pandemic
on our business and results of operations, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates or other
factors. Such risks and uncertainties may cause the statements to
be inaccurate and readers are cautioned not to place undue reliance
on such statements. Many of these risks are outside of the
Company’s control and could cause its actual results to differ
materially from those it thought would occur. The forward-looking
statements included in this press release are made only as of the
date hereof. The Company does not undertake, and specifically
declines, any obligation to update any such statements or to
publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as
required by law.
For further information, please refer to the
Risk Factors section in our Annual Report for the year ended
December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020
and other current reports and documents filed with the U.S.
Securities and Exchange Commission (SEC). You may obtain these
documents by visiting EDGAR on the SEC website at www.sec.gov.
Media Contact:
CENTOGENE
Melissa Hall
Corporate Communications
press@centogene.com
FTI Consulting
Bridie Lawlor
+1.917.929.5684
bridie.lawlor@fticonsulting.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024